{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T19:18:40Z","timestamp":1788031120662,"version":"build-2784847793"},"reference-count":34,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T00:00:00Z","timestamp":1732147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"name":"DAPA-HF"},{"name":"DELIVER"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background and Aims<\/jats:title>\n                  <jats:p>Individuals with heart failure (HF), other forms of cardiovascular disease, or kidney disease are at increased risk for the development and adverse health effects of diabetes. As such, prevention or delay of diabetes is an important treatment priority in these groups. The aim of this meta-analysis was to determine the effect of sodium-glucose co-transporter 2 inhibitors (SGLT2i) on incident diabetes in HF across the spectrum of left ventricular ejection fraction (LVEF) and across the broader spectrum of cardiovascular or kidney disease.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>First, the effects of dapagliflozin vs. placebo on new-onset diabetes were assessed in a pooled, participant-level analysis of the DAPA-HF and DELIVER trials. New-onset diabetes was defined as the new initiation of glucose-lowering therapy during follow-up, and time from randomization to new-onset diabetes was evaluated using Cox proportional hazards models. Second, PubMed and Embase were searched to identify large-scale randomized clinical outcomes trials (RCTs) comparing SGLT2i with placebo among adults with cardiovascular or kidney disease. A trial-level meta-analysis was then conducted to summarize the treatment effects of SGLT2i on the incidence of new-onset diabetes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In the pooled analysis of DAPA-HF and DELIVER including 5623 participants with HF but without diabetes at baseline, dapagliflozin reduced the incidence of new-onset diabetes by 33% [hazard ratio (HR), 0.67; 95% confidence interval (CI), .49\u2013.91; P = .012] when compared with placebo. There was no evidence of heterogeneity across the spectrum of continuous LVEF or key subgroups. Among seven complementary RCTs including 17 855 participants with cardiovascular or kidney disease, SGLT2i reduced the of new-onset diabetes by 26% (HR, 0.74; 95% CI .65\u2013.85; P &amp;lt; .001), with consistent effects across trials.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>SGLT2i reduced the incidence of new-onset diabetes among individuals with cardiovascular or kidney disease. These findings suggest that SGLT2i implementation may have an important ancillary benefit on prevention or delay of diabetes in these high-risk populations.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehae780","type":"journal-article","created":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T04:33:56Z","timestamp":1732163636000},"source":"Crossref","is-referenced-by-count":7,"title":["Sodium-glucose co-transporter 2 inhibitors and new-onset diabetes in cardiovascular or kidney disease"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2866-9414","authenticated-orcid":false,"given":"John W","family":"Ostrominski","sequence":"first","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital, Harvard Medical School, 75 Francis St. , Boston, MA 02115 ,","place":["USA"]},{"name":"Division of Endocrinology, Diabetes and Hypertension, Brigham and Women\u2019s Hospital, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats C","family":"H\u00f8jbjerg Lassen","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital, Harvard Medical School, 75 Francis St. , Boston, MA 02115 ,","place":["USA"]},{"name":"Department of Cardiology, Copenhagen University Hospital\u2014Herlev and Gentofte , Copenhagen ,","place":["Denmark"]},{"name":"Center for Translational Cardiology and Pragmatic Randomized Trials, Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian L","family":"Claggett","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital, Harvard Medical School, 75 Francis St. , Boston, MA 02115 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2377-1444","authenticated-orcid":false,"given":"Zi Michael","family":"Miao","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital, Harvard Medical School, 75 Francis St. , Boston, MA 02115 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio E","family":"Inzucchi","sequence":"additional","affiliation":[{"name":"Section of Endocrinology, Yale University School of Medicine , New Haven, CT ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5446-9969","authenticated-orcid":false,"given":"Kieran F","family":"Docherty","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay S","family":"Desai","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital, Harvard Medical School, 75 Francis St. , Boston, MA 02115 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4306-5317","authenticated-orcid":false,"given":"Pardeep S","family":"Jhund","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"K\u00f8ber","sequence":"additional","affiliation":[{"name":"Rigshospitalet, Copenhagen University Hospital , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Ponikowski","sequence":"additional","affiliation":[{"name":"Wroclaw Medical University , Wroclaw ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc S","family":"Sabatine","sequence":"additional","affiliation":[{"name":"TIMI Study Group, Cardiovascular Division, Brigham and Women\u2019s Hospital, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn S P","family":"Lam","sequence":"additional","affiliation":[{"name":"National Heart Centre Singapore and Duke-National University of Singapore ,","place":["Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe A","family":"Martinez","sequence":"additional","affiliation":[{"name":"Universidad Nacional de C\u00f3rdoba , C\u00f3rdoba ,","place":["Argentina"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf A","family":"de Boer","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Erasmus Medical Center , Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian F","family":"Hernandez","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Duke University School of Medicine , Durham, NC ,","place":["USA"]},{"name":"Duke Clinical Research Institute, Duke University , Durham, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjiv J","family":"Shah","sequence":"additional","affiliation":[{"name":"Feinberg Cardiovascular Research Institute, Northwestern University Feinberg School of Medicine , Chicago, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Petersson","sequence":"additional","affiliation":[{"name":"Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca , Gothenburg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Langkilde","sequence":"additional","affiliation":[{"name":"Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca , Gothenburg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6317-3975","authenticated-orcid":false,"given":"John J V","family":"McMurray","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D","family":"Solomon","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital, Harvard Medical School, 75 Francis St. , Boston, MA 02115 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0885-1953","authenticated-orcid":false,"given":"Muthiah","family":"Vaduganathan","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital, Harvard Medical School, 75 Francis St. , Boston, MA 02115 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,11,21]]},"reference":[{"key":"2024112104334253200_ehae780-B1","doi-asserted-by":"publisher","first-page":"e294","DOI":"10.1161\/CIR.0000000000000691","article-title":"Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association and the Heart Failure Society of America","volume":"140","author":"Dunlay","year":"2019","journal-title":"Circulation"},{"key":"2024112104334253200_ehae780-B2","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1161\/CIRCRESAHA.121.318241","article-title":"Cardiac energy metabolism in heart failure","volume":"128","author":"Lopaschuk","year":"2021","journal-title":"Circ Res"},{"key":"2024112104334253200_ehae780-B3","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1093\/eurjhf\/hfq160","article-title":"Heart failure severity, as determined by loop diuretic dosages, predicts the risk of developing diabetes after myocardial infarction: a nationwide cohort study","volume":"12","author":"Andersson","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"2024112104334253200_ehae780-B4","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1007\/s00125-014-3259-z","article-title":"Association of heart failure severity with risk of diabetes: a Danish nationwide cohort study","volume":"57","author":"Demant","year":"2014","journal-title":"Diabetologia"},{"key":"2024112104334253200_ehae780-B5","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.2337\/dci22-0014","article-title":"Heart failure: an underappreciated complication of diabetes. A consensus report from the American Diabetes Association","volume":"45","author":"Busui-Pop","year":"2022","journal-title":"Diabetes Care"},{"key":"2024112104334253200_ehae780-B6","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2024112104334253200_ehae780-B7","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2024112104334253200_ehae780-B8","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/S2213-8587(21)00295-3","article-title":"Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials","volume":"10","author":"Rossing","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2024112104334253200_ehae780-B9","doi-asserted-by":"publisher","first-page":"586","DOI":"10.2337\/dc20-1675","article-title":"Dapagliflozin and the incidence of type 2 diabetes in patients with heart failure and reduced ejection fraction: an exploratory analysis from DAPA-HF","volume":"44","author":"Inzucchi","year":"2021","journal-title":"Diabetes Care"},{"key":"2024112104334253200_ehae780-B10","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.jacc.2019.11.031","article-title":"Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors. JACC state-of-the-art review","volume":"75","author":"Zelniker","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2024112104334253200_ehae780-B11","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1016\/j.jchf.2024.03.003","article-title":"Controversies and conundrums in cardiac cachexia: key questions about wasting in patients with HFrEF","volume":"12","author":"Ilonze","year":"2024","journal-title":"JACC Heart Fail"},{"key":"2024112104334253200_ehae780-B12","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1001\/jamacardio.2023.0957","article-title":"Skeletal muscle mitochondrial respiration and exercise intolerance in patients with heart failure with preserved ejection fraction","volume":"8","author":"Scandalis","year":"2023","journal-title":"JAMA Cardiol"},{"key":"2024112104334253200_ehae780-B13","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1016\/j.jacc.2014.08.036","article-title":"Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction","volume":"64","author":"Mentz","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2024112104334253200_ehae780-B14","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1038\/ki.2015.305","article-title":"Molecular mechanisms of insulin resistance in chronic kidney disease","volume":"88","author":"Thomas","year":"2015","journal-title":"Kidney Int"},{"key":"2024112104334253200_ehae780-B15","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2024112104334253200_ehae780-B16","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagiflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"2024112104334253200_ehae780-B17","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.2337\/dc24-S002","article-title":"Diagnosis and classification of diabetes: standards of care in diabetes\u20142024","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2024","journal-title":"Diabetes Care"},{"key":"2024112104334253200_ehae780-B18","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"2024112104334253200_ehae780-B19","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2024112104334253200_ehae780-B20","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1161\/CIRCULATIONAHA.122.059785","article-title":"Empagliflozin for heart failure with preserved left ventricular ejection fraction with and without diabetes","volume":"146","author":"Filippatos","year":"2022","journal-title":"Circulation"},{"key":"2024112104334253200_ehae780-B21","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"2024112104334253200_ehae780-B22","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"The EMPA-KIDNEY Collaborative Group","year":"2023","journal-title":"N Engl J Med"},{"key":"2024112104334253200_ehae780-B23","doi-asserted-by":"publisher","first-page":"EVIDoa2300286","DOI":"10.1056\/EVIDoa2300286","article-title":"Dapagliflozin in myocardial infarction without diabetes or heart failure","volume":"3","author":"James","year":"2024","journal-title":"NEJM Evid"},{"key":"2024112104334253200_ehae780-B24","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet"},{"key":"2024112104334253200_ehae780-B25","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1001\/jamacardio.2023.3241","article-title":"Prevalence and overlap of cardiac, renal, and metabolic conditions in US adults, 1999\u20132020","volume":"8","author":"Ostrominski","year":"2023","journal-title":"JAMA Cardiol"},{"key":"2024112104334253200_ehae780-B26","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1093\/eurheartj\/ehv728","article-title":"Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME trial","volume":"37","author":"Fitchett","year":"2016","journal-title":"Eur Heart J"},{"key":"2024112104334253200_ehae780-B27","doi-asserted-by":"publisher","first-page":"915","DOI":"10.2337\/dc08-1709","article-title":"Predictors of development of diabetes in patients with chronic heart failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM)","volume":"32","author":"Preiss","year":"2009","journal-title":"Program. Diabetes Care"},{"key":"2024112104334253200_ehae780-B28","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.2337\/dc24-S003","article-title":"Prevention or delay of diabetes and associated comorbidities: Standards of Care in Diabetes\u20142024","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2024","journal-title":"Diabetes Care"},{"key":"2024112104334253200_ehae780-B29","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1007\/s00125-017-4361-9","article-title":"Metformin for diabetes prevention: insights gained from the Diabetes Prevention Program\/Diabetes Prevention Program Outcomes Study","volume":"60","author":"Aroda","year":"2017","journal-title":"Diabetologia"},{"key":"2024112104334253200_ehae780-B30","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/S2213-8587(21)00310-7","article-title":"SGLT-2 inhibitors: does it matter if they prevent type 2 diabetes","volume":"10","author":"Cheng","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2024112104334253200_ehae780-B31","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s00125-014-3196-x","article-title":"Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes","volume":"57","author":"Polidori","year":"2014","journal-title":"Diabetologia"},{"key":"2024112104334253200_ehae780-B32","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trial","volume":"400","author":"Nuffield Department of Population Health Renal Studies Group","year":"2022","journal-title":"Lancet"},{"key":"2024112104334253200_ehae780-B33","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1016\/j.jchf.2023.03.007","article-title":"Polypharmacy and optimization of guideline-directed medical therapy in heart failure: the GUIDE-IT trial","volume":"11","author":"Khan","year":"2023","journal-title":"JACC Heart Fail"},{"key":"2024112104334253200_ehae780-B34","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","article-title":"Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021","volume":"402","author":"GBD 2021 Diabetes Collaborators","year":"2023","journal-title":"Lancet"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article-pdf\/doi\/10.1093\/eurheartj\/ehae780\/60774435\/ehae780.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article-pdf\/doi\/10.1093\/eurheartj\/ehae780\/60774435\/ehae780.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T04:34:03Z","timestamp":1732163643000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article\/doi\/10.1093\/eurheartj\/ehae780\/7905901"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,21]]},"references-count":34,"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehae780","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,21]]},"article-number":"ehae780"}}